{"meta":{"query_hash":"592b5e7f5b1c","filters":{"venue":"Current Drug Targets - Infectious Disorders"},"cohort_total":5,"direct_labels_cover":0,"predictions_cover":5,"exported":5,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/592b5e7f5b1c","api":"https://metacan.xera.ac/api/v1/cohort?venue=Current+Drug+Targets+-+Infectious+Disorders"},"results":[{"id":"W2000122784","doi":"10.2174/1568005053174609","title":"Advances on Cyclin-dependent Kinases (CDKs) as Novel Targets for Antiviral Drugs","year":2005,"lang":"en","type":"review","venue":"Current Drug Targets - Infectious Disorders","topic":"Cancer-related Molecular Pathways","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heritage Medical Research Clinic","funders":"","keywords":"Cyclin-dependent kinase; Biology; Antiviral drug; Viral replication; Kinase; Virology; Drug discovery; Drug resistance; Virus; Cancer; Bioinformatics; Cell cycle; Cell biology; Genetics","score_opus":0.023726204393084132,"score_gpt":0.35447768967265625,"score_spread":0.3307514852795721,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2000122784","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000674463,0.9732979,0.001199605,0.00015430556,0.007639961,0.0068642935,0.0006737538,0.00062528136,0.009477475],"genre_scores_gemma":[0.0014116887,0.99184644,0.00015525676,0.00019787608,0.0015089287,0.0018476461,0.002151168,0.00046672585,0.00041424527],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99379885,0.00018518072,0.0015694842,0.001970053,0.0010288573,0.0014475707],"domain_scores_gemma":[0.9965104,0.00047383402,0.00116664,0.0011448938,0.00024645112,0.00045777706],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00045809848,0.0018014129,0.003375002,0.0010263599,0.00044248812,0.000102050384,0.00049870304,0.00064271194,0.00017608727],"category_scores_gemma":[0.0006252088,0.001634316,0.002508491,0.0007094922,0.0002785311,0.000282031,0.00019458665,0.0019034289,0.00061392825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001254867,0.0023314115,0.000026190888,0.013197831,0.00054082414,0.000012031552,0.00019274974,0.00010115802,0.0000031311367,0.00029117297,0.005280245,0.97789776],"study_design_scores_gemma":[0.004153899,0.00072029413,0.0000030787023,0.011820163,0.002468571,0.00003955299,0.00006232097,0.000060031514,0.00003763103,0.00032598712,0.97876704,0.001541418],"about_ca_topic_score_codex":0.00007626962,"about_ca_topic_score_gemma":0.00030226173,"teacher_disagreement_score":0.9763563,"about_ca_system_score_codex":0.0011756887,"about_ca_system_score_gemma":0.0011403693,"threshold_uncertainty_score":0.9994731},"labels":[],"label_agreement":null},{"id":"W2052987107","doi":"10.2174/1568005014606143","title":"Lipopolysaccharide as a Target for the Development of Novel Therapeutics in Gram-Negative Bacteria","year":2001,"lang":"en","type":"review","venue":"Current Drug Targets - Infectious Disorders","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Lipopolysaccharide; Gram-negative bacteria; Lipid A; Bacteria; Biosynthesis; Function (biology); In vitro; Computational biology; Biology; Chemistry; Biochemistry; Microbiology; Cell biology; Escherichia coli; Immunology; Enzyme; Genetics","score_opus":0.03574007799130596,"score_gpt":0.3414995194850012,"score_spread":0.3057594414936952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052987107","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003859398,0.9826553,0.008589398,0.000023799104,0.0018033963,0.0027109757,0.00016234987,0.000025538277,0.00016986235],"genre_scores_gemma":[0.0028874865,0.9939786,0.0015994015,0.000022702592,0.00020913732,0.00045850463,0.00060291553,0.0001206393,0.00012059268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723786,0.00013177826,0.0011207658,0.00072241185,0.00020986347,0.00057732913],"domain_scores_gemma":[0.99816674,0.0002036165,0.000820252,0.0006051055,0.00013189978,0.000072401985],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004496917,0.00070261623,0.001114567,0.0001772511,0.00018954891,0.00004974994,0.0006272992,0.00033846285,0.00003324499],"category_scores_gemma":[0.00020816528,0.000526441,0.0005710045,0.00029913546,0.00024643456,0.000009802717,0.00019897311,0.0003651901,0.0000088716915],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009413638,0.0011221804,0.0009917981,0.005842499,0.0010383183,4.0164383e-7,0.0006389283,0.000024774103,0.00040948973,0.00014850346,0.00045809307,0.9892309],"study_design_scores_gemma":[0.0008401712,0.00009779807,0.00008051943,0.001511618,0.0002719091,0.0000050048175,0.00012522533,0.000016203541,0.00050928263,0.00020941105,0.9957018,0.0006310465],"about_ca_topic_score_codex":0.00004130978,"about_ca_topic_score_gemma":0.0006409213,"teacher_disagreement_score":0.9952437,"about_ca_system_score_codex":0.00012449201,"about_ca_system_score_gemma":0.00082203874,"threshold_uncertainty_score":0.9997187},"labels":[],"label_agreement":null},{"id":"W2081852455","doi":"10.2174/1568005023342362","title":"Strategic Targeting of Essential Host-pathogen Interactions in Chlamydial Disease","year":2002,"lang":"en","type":"review","venue":"Current Drug Targets - Infectious Disorders","topic":"Reproductive tract infections research","field":"Immunology and Microbiology","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton","funders":"","keywords":"Chlamydiae; Biology; Intracellular parasite; Pathogen; Chlamydia; Virulence; Microbiology; Chlamydia trachomatis; Human pathogen; Intracellular; Virology; Immunology; Bacteria; Gene; Genetics","score_opus":0.04407964193876839,"score_gpt":0.35716129643002725,"score_spread":0.31308165449125885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081852455","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002592924,0.98588735,0.000043418982,0.000028862105,0.006541434,0.0022054384,0.00043382368,0.00017279065,0.002093969],"genre_scores_gemma":[0.029286606,0.9675342,0.0000056778335,0.000002278599,0.00026374683,0.0007016838,0.0016789477,0.00012130981,0.00040557902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99462473,0.0014010157,0.0015397996,0.0012685858,0.00016864958,0.0009972289],"domain_scores_gemma":[0.99745953,0.0005042927,0.0008554138,0.0008355566,0.00023114553,0.000114072274],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00061460136,0.00088418333,0.0019056872,0.0016775695,0.00034984358,0.000056531855,0.0005576061,0.00029754743,0.00216388],"category_scores_gemma":[0.0006553402,0.0008416662,0.0011235479,0.0013133237,0.00058362156,0.0003290999,0.000276934,0.002574433,0.0010747359],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012368607,0.009556095,0.0065901037,0.02262617,0.0017233363,0.000026278009,0.0009777974,0.00016489673,0.00040547672,0.00097390043,0.005732245,0.9511],"study_design_scores_gemma":[0.00091791764,0.00007171719,0.00024317326,0.0027221725,0.0005980672,0.00002855396,0.00011345942,0.000010774216,0.000024683879,0.00040184997,0.9939894,0.0008782264],"about_ca_topic_score_codex":0.0004237191,"about_ca_topic_score_gemma":0.00037320316,"teacher_disagreement_score":0.98825717,"about_ca_system_score_codex":0.00041973538,"about_ca_system_score_gemma":0.0006194269,"threshold_uncertainty_score":0.99972665},"labels":[],"label_agreement":null},{"id":"W2082634748","doi":"10.2174/1568005014606017","title":"History of Vaccines and Positioning of Current Trends","year":2001,"lang":"en","type":"article","venue":"Current Drug Targets - Infectious Disorders","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Medicines Canada","funders":"","keywords":"Milestone; Civilization; Infectious disease (medical specialty); Medicine; Virology; Disease; Political science; History; Pathology","score_opus":0.01811441038436491,"score_gpt":0.2885642788367619,"score_spread":0.270449868452397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2082634748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86982787,0.11665383,0.00027863434,0.0002516437,0.002052731,0.00028373618,0.000018269242,0.00010884236,0.010524474],"genre_scores_gemma":[0.9812708,0.01825665,0.000035845136,0.000022055443,0.00009215534,0.000032097145,0.00003674878,0.000025323108,0.00022833845],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987215,0.000053666485,0.00045080812,0.00027383282,0.00023596644,0.00026421907],"domain_scores_gemma":[0.99921864,0.00006626415,0.00023876075,0.00020816759,0.00016571823,0.000102424514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013467376,0.00022292844,0.00049647206,0.00040234823,0.0000699876,0.0000036300519,0.000055789315,0.00004074202,0.00020245787],"category_scores_gemma":[0.00012712537,0.00021306923,0.00014755684,0.00027305473,0.00019160843,0.00011156176,0.0000666255,0.00020720331,0.000005544363],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049768812,0.00067939266,0.7982526,0.00044588337,0.00010229844,0.0000013675203,0.0021850755,0.000007905804,0.00019564874,0.00026212225,0.011722248,0.18609568],"study_design_scores_gemma":[0.003949931,0.00052013714,0.6521229,0.00077236583,0.00047159,0.000031467902,0.00015899086,0.00036947386,0.0002901016,0.0009726764,0.33983654,0.0005038426],"about_ca_topic_score_codex":0.00047440207,"about_ca_topic_score_gemma":0.00086538435,"teacher_disagreement_score":0.32811427,"about_ca_system_score_codex":0.00021261525,"about_ca_system_score_gemma":0.000094319344,"threshold_uncertainty_score":0.86887115},"labels":[],"label_agreement":null},{"id":"W2166290770","doi":"10.2174/1568005024605855","title":"Clinical Development of Cationic Antimicrobial Peptides: From Natural to Novel Antibiotics","year":2002,"lang":"en","type":"review","venue":"Current Drug Targets - Infectious Disorders","topic":"Antimicrobial Peptides and Activities","field":"Immunology and Microbiology","cited_by":368,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; University of British Columbia; Canada Research Chairs; Cystic Fibrosis Foundation","keywords":"Antimicrobial; Antibiotics; Antimicrobial peptides; Cationic polymerization; Biology; Microbiology; Computational biology; Chemistry; Organic chemistry","score_opus":0.03686783319529565,"score_gpt":0.32702904801601973,"score_spread":0.2901612148207241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166290770","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044627427,0.9823461,0.00077385735,0.000026428244,0.0100231115,0.0013339875,0.0006292514,0.00016785858,0.000236622],"genre_scores_gemma":[0.014748639,0.9810528,0.0007525326,0.000051871735,0.00023069906,0.000015118995,0.00246189,0.000116745716,0.000569657],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957485,0.00029755986,0.002053398,0.0010273319,0.00009751997,0.00077565305],"domain_scores_gemma":[0.99760157,0.00043531397,0.0011363227,0.0005935717,0.00015106084,0.000082133316],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033604068,0.0009310786,0.0027243274,0.00044618876,0.00042466936,0.00005398852,0.00065988075,0.0006148481,0.00030294148],"category_scores_gemma":[0.00018089742,0.00084459287,0.0011172066,0.00043172747,0.0004764176,0.00014833921,0.00041282136,0.0014260038,0.0015178733],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001726635,0.0019804148,0.00043805566,0.0035155036,0.0011558159,6.0828796e-7,0.0007996117,0.0000071345994,0.00017782328,0.000046249283,0.02791067,0.9639509],"study_design_scores_gemma":[0.0009716905,0.00005185164,0.00009915501,0.005743395,0.00061551895,0.000011029935,0.00005489543,0.0000017134515,0.00021824293,0.000013556398,0.9912491,0.0009698922],"about_ca_topic_score_codex":0.00017390282,"about_ca_topic_score_gemma":0.00047227577,"teacher_disagreement_score":0.9633384,"about_ca_system_score_codex":0.00019488031,"about_ca_system_score_gemma":0.0005443149,"threshold_uncertainty_score":0.9994005},"labels":[],"label_agreement":null}]}